Welcome to our dedicated page for Thermo Fishr Sci SEC filings (Ticker: TMO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Thermo Fisher Scientific Inc. (NYSE: TMO) files a wide range of documents with the U.S. Securities and Exchange Commission, and this page aggregates those SEC filings for investors tracking TMO. The company’s common stock and multiple series of senior notes are listed on the New York Stock Exchange, and its filings describe the terms, rankings and covenants of these securities, as well as material events affecting the business.
Recent Form 8‑K filings illustrate the types of information Thermo Fisher discloses. Several 8‑Ks detail public offerings of senior notes in U.S. dollars and euros, including maturities, interest payment schedules, redemption provisions, change‑of‑control protections and the use of proceeds for general corporate purposes such as acquisitions, debt repayment or refinancing, working capital, capital expenditures or equity repurchases. Other 8‑Ks report the completion of the acquisition of Solventum Corporation’s purification and filtration business and the signing of a definitive agreement to acquire Clario Holdings, Inc.
Thermo Fisher also uses 8‑K filings to communicate quarterly financial results, leadership transitions and organizational changes. For example, filings describe announcements of financial results for specific fiscal quarters, the planned retirement of the Senior Vice President and Chief Financial Officer and the appointment of a successor, and updates to the organizational structure and leadership team, including changes in executive roles.
On Stock Titan’s SEC filings page for TMO, users can access these current reports alongside other registered securities information, and benefit from AI‑powered summaries that explain key terms, highlight significant covenants, and clarify how new debt offerings, acquisitions, leadership changes or other material events may affect Thermo Fisher Scientific’s capital structure and corporate profile.
Thermo Fisher Scientific reported Q1 2026 revenue of $11.01B, up 6% year over year, with organic revenue growth of 1%. GAAP operating income was $1.86B and diluted EPS rose to $4.43 from $3.98, helped by a low 4.0% effective tax rate.
The company generated free cash flow of $825M and ended the quarter with $3.25B in cash and $43.16B of total debt. It closed the $9.10B acquisition of Clario to expand clinical research offerings and agreed to sell its microbiology business for about $1.08B. Thermo Fisher also repurchased $3.0B of stock and recorded $49M of restructuring costs, with about $290M of additional actions identified, mainly in Laboratory Products and Biopharma Services.
Thermo Fisher Scientific Inc Schedule 13G: Vanguard Capital Management reports beneficial ownership of 28,008,822 shares of Thermo Fisher common stock, representing 7.53% of the class as of 03/31/2026. The filing states these holdings include securities held by Vanguard funds and managed accounts where Vanguard affiliates exercise dispositive power.
Thermo Fisher Scientific President & COO Gianluca Pettiti sold 400 shares of Common Stock in an open-market transaction. The sale occurred on April 27, 2026 at a price of $462.66 per share. The transaction was made under a Rule 10b5-1 trading plan adopted on September 12, 2025. After this sale, Pettiti continues to hold 25,050.832 shares of Thermo Fisher Scientific Common Stock directly.
Gianluca Pettiti submitted a Form 144 notice indicating 400 shares of Common Stock tied to a restricted stock vesting on 02/28/2024 are being offered for sale. The filing lists a brokerage account at Fidelity Brokerage Services LLC and shows a prior sale of 400 shares on 02/09/2026 for $216,480.00.
Thermo Fisher Scientific Inc. reported solid first quarter 2026 results, with revenue up 6% to $11.01 billion and organic revenue growth of 1%. GAAP diluted EPS rose 11% to $4.43, while adjusted EPS increased 6% to $5.44, reflecting higher operating income and slightly improved GAAP operating margin of 16.9%.
Adjusted operating income grew to $2.40 billion with an adjusted operating margin of 21.8%. Free cash flow more than doubled to $825 million. The company completed the acquisition of Clario, repurchased $3.0 billion of stock, increased its dividend by 10%, and continued launching new products and strategic collaborations.
Thermo Fisher Scientific is asking shareholders to vote on electing 11 directors, approving an advisory say‑on‑pay resolution, and ratifying its independent auditors at the 2026 virtual annual meeting. The proxy highlights 2025 results, with revenue up 4% to $44.56 billion, GAAP diluted EPS rising 7% to $17.74, adjusted EPS of $22.87, and free cash flow of $6.34 billion. The company deployed about $16.5 billion of capital, including $13 billion for M&A such as the Filtration and Separation business from Solventum and an agreement to acquire Clario, and returned $3.6 billion via buybacks and dividends, achieving 11.3% adjusted ROIC. The Board emphasizes strong governance, active refreshment, and extensive shareholder engagement after only about 36% support on the 2025 say‑on‑pay vote, leading to 2026 compensation design changes and a long‑dated, performance‑based CEO retention grant tied to relative TSR versus the S&P 500.
SPERLING SCOTT M reported acquisition or exercise transactions in this Form 4 filing.
Thermo Fisher Scientific director Scott M. Sperling received a grant of 89.780 Phantom Stock Units, each convertible into one share of Common Stock. The units were credited on the director’s deferred compensation account at a price of $473.36 per unit under the company’s Deferred Compensation Plan for Directors.
Following this grant, Sperling now holds a total of 17,591.800 stock units in this account. These units are scheduled to be distributed in shares of Common Stock when his board service ends for any reason or if there is a change of control.
Keith R. Alexandra reported acquisition or exercise transactions in this Form 4 filing.
Thermo Fisher Scientific director Keith R. Alexandra received a grant of 66.02 Phantom Stock Units tied to common shares. These units were credited on March 28, 2026 at a reference price of $473.36 per unit under the company’s Deferred Compensation Plan for Directors. Each unit is convertible into one share of common stock and is distributable as stock when his board service ends or upon a change of control. Following this grant, Alexandra holds a total of 1,270.44 Phantom Stock Units directly.
Lynch Karen S reported acquisition or exercise transactions in this Form 4 filing.
Thermo Fisher Scientific director Karen S. Lynch received 66.02 Phantom Stock Units tied to common stock as deferred compensation. These units are credited under the company’s Deferred Compensation Plan for Directors at $473.36 per unit and are convertible into common stock on a 1-for-1 basis.
Following this grant, Lynch holds a total of 291.49 phantom units. The units are scheduled to be distributed in stock after her board service ends for any reason or upon a change of control, aligning compensation with long-term shareholder value.